Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bio-Succinic Acid Demonstrates Substantial Benefits Toward Growth Performance in Animal Feed Commercial Trial

Canada NewsWire

MONTREAL, Jan. 29, 2018 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) (TSX: BIOA) - a leader in renewable materials, is pleased to announce the results of an independent commercial trial conducted with a leading North American feed formulator, on the effectiveness of BioAmber's Bio-Succinic Acid, BIO-SA™, as an ingredient in Animal Feed for nursery pigs.

In a commercial study co-sponsored by BioAmber, BIO-SA™ feed supplementation demonstrated substantial benefits towards the growth performance and gut health in nursery pigs under dietary and environmental challenges. Specifically, the addition of bio-succinic acid to feed resulted in material increases in the average daily weight gain of nursery pigs. In another series of studies, in vitro tests have confirmed that BIO-SA™ exhibits antimicrobial activity against certain microorganisms at lower concentrations than other organic acids. Results obtained by BioAmber indicate that BIO-SA™ in feed additives could improve overall growth performance and reduce detrimental animal health conditions.

Succinic acid is listed by The Association of American Feed Control Officials (AAFCO) and the European Union Register of Feed Additives, for immediate use in animal feed formulations.

BioAmber CEO Richard Eno stated, "Animal feed represents an extremely large market opportunity for BioAmber, and these studies show that our product could play an important role in antibiotic replacement. BIO-SA™ can assist the Animal Feed industry's continued move away from antibiotics as well as its ongoing drive for enhanced feed productivity, while at the same time improving the overall sustainability of the supply chain. Formulation and early stage market testing continues as we move towards ongoing, commercial sales in this important sector."

BioAmber will be attending the International Production & Processing Expo (IPPE), the world's largest annual poultry, feed and meat technology exposition, in Atlanta, GA from January 30 through February 1, 2018. Please contact Paul Petersen – Vice President of Sales at paul.petersen@bio-amber.com for more information.

About BioAmber
BioAmber (NYSE: BIOA, TSX: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward- looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber's public filings with the SEC, including the "Risk Factors" section of BioAmber's Annual Report on Form 10-K and the most recent quarterly report on Form 10-Q.

 

SOURCE BioAmber Inc.

View original content: http://www.newswire.ca/en/releases/archive/January2018/29/c3883.html

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today